Coleus forskohlii diterpene

Plain-language summaryIntrigue 55 / 100

Forskolin is a diterpene from the Coleus forskohlii plant root. It directly activates adenylyl cyclase, raising intracellular cAMP. Used in research as a cAMP elevator and as a supplement for weight loss (with limited evidence). Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

Mature cAMP-elevating probe with a unique mechanism but weak clinical translation and low novelty

Cap applied Common OTC food/herb — max 35

Look, forskolin has a genuinely interesting mechanism on paper. Direct activation of adenylate cyclase, bypassing G-protein-coupled receptors entirely, means you can elevate intracellular cAMP in essentially any cell type without needing a receptor-level handle. Thats a real pharmacological property. The problem is that “raises cAMP” is also one of the most crowded and least surprising things you can do in a cell biology experiment. Caffeine does it. IBMX does it. Rolipram does it. The question isnt whether you can raise cAMP; its whether you have something meaningful to say once you do.

The clinical story for forskolin is mostly disappointment. The obesity work is the most widely cited, and it’s not good. The Godard et al. 2005 RCT in overweight men showed some body composition signal; a companion trial in women did not replicate the lean mass effect. Glaucoma is the one application where topical ophthalmic formulations have shown real intraocular pressure reduction, but that work belongs to a specific delivery context and formulation space, not to standardized coleus extract as broadly studied. Cardiovascular work from the 1980s and 90s was conducted under IV administration conditions that don’t translate to anything commercially or bench-practically relevant today. We don’t think there is a compelling modern indication sitting here waiting to be unlocked.

The mechanism differentiation is the only thing keeping this compound from scoring lower. You cannot directly activate adenylate cyclase with most available tools, so forskolin genuinely earns its place as a positive control for cAMP-dependent pathway studies in cell culture. That’s real bench value. But it’s not indispensable. Dibutyryl-cAMP analogs, cholera toxin in specific contexts, and phosphodiesterase inhibitors all compete for the same experimental slot. Forskolin is convenient and cheap, not irreplaceable.

What we dont like here is the gap between mechanism plausibility and clinical delivery. The translational arrow points nowhere useful in 2026. Weight loss signal in humans is unimpressive and inconsistent across cohorts and sexes. Cardiovascular effects are pharmacologically interesting in isolated myocardium preparations but haven’t generated anything a modern cardiologist would act on. The glaucoma angle is arguably the strongest and most specific, but it isnt what drives the supplement market’s interest or the research community’s attention to this compound.

Honestly, if you’re building a research program around cAMP signaling, you’d include forskolin as a probe and positive control, not as the headline compound. Compared to what’s happening in dual and triple incretin biology, mitochondrial-derived peptides, and NNMT inhibition, a four-decade-old plant diterpene doesn’t move the needle. There’s nothing wrong with it as a tool. It just doesn’t represent where the interesting science is happening right now, and the supplement-market noise around it obscures rather than sharpens the actual research question.

Novelty: 20
Mechanism promise: 38
In-category differentiation: 42
Evidence quality: 36
Translational signal: 30
Research bench value: 60

Rationale Forskolin’s direct adenylate cyclase activation is mechanistically distinct from receptor-mediated cAMP elevation and earns genuine bench credit as a positive control tool, but the compound is four decades old, its clinical signal across obesity and cardiovascular indications is inconsistent and modest, and the OTC herb cap binds at 35 given its primary commercial identity as a Coleus forskohlii extract supplement.

Coleus forskohlii diterpene

A labdane diterpene from Coleus forskohlii root with adenylate cyclase activation activity, used for cardiovascular and metabolic applications.

Abstract

Forskolin (CAS 66575-29-9; molecular formula C22H34O7; molecular weight 410.50) is a labdane diterpene isolated from the root of Coleus forskohlii (Plectranthus barbatus), a perennial plant native to India. The compound is a direct activator of adenylate cyclase (independent of receptor activation), elevating intracellular cAMP across many cell types. Pharmacology includes positive inotropy (cardiac), vasodilation, lipolysis, and bronchodilation. Forskolin has been studied for hypertension, cardiovascular dysfunction, glaucoma, and obesity (the latter primarily in dietary supplement form). Doses are typically 250 to 500 mg of standardized extract (10 to 20 percent forskolin) per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-177Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Coleus forskohlii diterpene

Forskolin

Abstract

Read the full monograph